TrialThe Lancet. Infectious diseases2022

Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study.

Desiree Witte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.